Gt biopharma presents trike® nanobody pipeline (gtb-5550) preclinical multiple myeloma proof-of-concept data at 2022 ebmt annual meeting

-          gtb-5550 trike significantly enhances nk cell mediated killing of myeloma cells, even in the relatively low b7-h3-expressing h929 cell line -          preclinical data demonstrates gtb-5550 reverses mdsc-induced myeloma growth brisbane, calif. , march 21, 2022 /prnewswire/ -- gt biopharma, inc. ("the company") (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary tri-specific natural killer (nk) cell engager, trike® protein biologic technology platform, announced today, preclinical data to be presented at the hybrid 48th european society for blood and marrow transplantation annual meeting (ebmt).
GTBP Ratings Summary
GTBP Quant Ranking